Article thumbnail

Lack of allele-specific efficacy of a bivalent AMA1 malaria vaccine

By Amed Ouattara, Jianbing Mu, Shannon Takala-Harrison, Renion Saye, Issaka Sagara, Alassane Dicko, Amadou Niangaly, Junhui Duan, Ruth D Ellis, Louis H Miller, Xin-zhuan Su, Christopher V Plowe and Ogobara K Doumbo
Topics: Research
Publisher: BioMed Central
OAI identifier: oai:pubmedcentral.nih.gov:2908102
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles

Citations

  1. (2009). A: A randomized controlled phase 2 trial of the blood stage AMA1-C1/Alhydrogel malaria vaccine in children in Mali. Vaccine
  2. (2001). AA: Longitudinal study of natural immune responses to the Plasmodium falciparum apical membrane antigen (AMA-1) in a holoendemic region of malaria in western Kenya: Asembo Bay Cohort Project VIII. Am J Trop Med Hyg
  3. (2008). AF: Mixed allele malaria vaccines: Host protection and within-host selection. Vaccine
  4. (2005). AH: Structure of AMA1 from Plasmodium falciparum reveals a clustering of polymorphisms that surround a conserved hydrophobic pocket. Proc Natl Acad Sci USA
  5. (2002). Alpers MP: A recombinant blood-stage malaria vaccine reduces Plasmodium falciparum density and exerts selective pressure on parasite populations in a phase 1-2b trial in Papua New Guinea. J Infect Dis
  6. (2001). Anders RF: Specificity of the Protective Antibody Response to apical membrane antigen 1. Infect Immun
  7. (2009). AP: A Phase 1 study of the blood-stage malaria vaccine candidate AMA1-C1/Alhydrogel with CPG 7909, using two different formulations and dosing intervals. Vaccine
  8. (2007). AW: Apical membrane antigen 1: a malaria vaccine candidate in review. Trends Parasitol
  9. (2003). BM: Protective efficacy of the RTS, S/ ASO2 Plasmodium falciparum malaria vaccine is not strain specific. Am J Trop Med Hyg
  10. (2010). Cite this article as: Ouattara et al., Lack of allele-specific efficacy of a bivalent AMA1 malaria vaccine Malaria Journal
  11. (2006). CJ: RTS, S/AS02A malaria vaccine does not induce parasite CSP T cell epitope selection and reduces multiplicity of infection. PLoS Clin Trials
  12. (2006). Crabb BS: Invasion of red blood cells by malaria parasites. Cell
  13. (2010). CV: Received: 29
  14. (2008). CV: Safety and immunogenicity of an AMA-1 malaria vaccine in Malian adults: results of a phase 1 randomized controlled trial. PLoS ONE
  15. (2007). DE: Structural basis of antigenic escape of a malaria vaccine candidate.
  16. (2005). Diakite : Ogobara Doumbo Ok: Season, fever prevalence and pyrogenic threshold for malaria disease definition in an endemic area of Mali. Trop Med Int Health
  17. (1994). DL: High prevalence of natural antibodies against Plasmodium falciparum 83-kilodalton apical membrane antigen (PF83/AMA-1) as detected by capture-enzyme-linked immunosorbent assay using full-length baculovirus recombinant PF83/AMA-1. Am J Trop Med Hyg
  18. (2003). DNA polymorphism analyses by a coalescent and other methods. Bioinformatics
  19. (2009). Doumbo OK: A randomized and controlled Phase 1 study of the safety and immunogenicity of the AMA1-C1/Alhydrogel + CPG 7909 vaccine for Plasmodium falciparum malaria in semi-immune Malian adults. Vaccine
  20. (2008). Doumbo OK: Phase 1 study of a combination AMA1 blood stage malaria vaccine in Malian children. PLoS ONE
  21. (2003). FA: Geographical structure of diversity and differences between symptomatic and asymptomatic infections for Plasmodium falciparum vaccine candidate AMA1. Infect Immun
  22. (2003). Inference of population structure using multilocus genotype data: Linked loci and correlated allele frequencies. Genetics
  23. (2003). Invasion-inhibitory antibodies inhibit proteolytic processing of apical membrane antigen1 of Plasmodium falciparum merozoites. Proc Natl Acad Sci USA
  24. (2002). LH: Vaccination of monkeys with recombinant Plasmodium falciparum apical membrane antigen 1 confers protection against blood-stage malaria. Infect Immun
  25. (2007). Molecular Evolutionary Genetics Analysis (MEGA) software version 4.0. Mol Biol Evol
  26. (2007). Mueller AK: Vaccines against malaria - an update.
  27. (2008). Phase 1 trial of AMA1-C1/Alhydrogel plus CPG 7909: an asexual blood-stage vaccine for Plasmodium falciparum malaria. PLoS ONE
  28. (2009). Plowe CV: Genetic diversity and malaria vaccine design, testing, and efficacy: Preventing and overcoming "vaccine resistant malaria. Parasite Immunol
  29. (2008). Population structure of the genes encoding the polymorphic Plasmodium falciparum apical membrane antigen 1: Implications for vaccine design. Proc Natl Acad Sci USA
  30. (1998). Pye: Immunisation with recombinant AMA-1 protects mice against infection with Plasmodium chabaudi. Vaccine
  31. (2007). Reed ZH: Asexual blood-stage malaria vaccine development: facing the challenges. Curr Opin Infect Dis
  32. (1996). RF: Protective immune responses to apical membrane antigen 1 of Plasmodium chabaudi involve recognition of strain-specific epitopes. Infect Immun
  33. (2002). RS: Structure of domain III of the blood stage malaria vaccine candidate, Plasmodium falciparum apical membrane antigen 1. J Mol Biol
  34. (1982). S: Rat monoclonal antibodies which inhibit the in vitro multiplication of Plasmodium knowlesi. Clin Exp Immunol
  35. (2009). SL: The potential role of vaccines in the elimination of falciparum malaria and the eventual eradication of malaria.
  36. (2002). Stowers AW: In vitro studies with recombinant Plasmodium falciparum apical membrane antigen 1 (AMA1): production and activity of an AMA1 vaccine and generation of a multiallelic response. Infect Immun
  37. (1984). The Fab fragments of monoclonal IgG to a merozoite surface antigen inhibit Plasmodium knowlesi invasion of erythrocytes. Mol Biochem Parasitol
  38. (2005). The global distribution of clinical episodes of Plasmodium falciparum malaria. Nature
  39. (2002). Thomas AW: High-level expression of the malaria blood-stage vaccine candidate Plasmodium falciparum apical membrane antigen-1 and induction of antibodies that inhibit erythrocyte invasion. Infect Immun
  40. (1998). Thomas AW: Precise timing of expression of a Plasmodium falciparum-derived transgene in Plasmodium berghei is a critical determinant of subsequent subcellular localization.